(Il Sole 24 Ore Radiocor) – Roche became the leader on the Zurich Stock Exchange thanks to the positive results it recorded third stage of study on a treatment drugs from breast cancer. Shares of the Swiss pharmaceutical giant posted the biggest increase in the benchmark index, among the top performers in the Stoxx Europe 600. Roche has announced “positive results” from the third phase of the lidERA Breast Cancer study, which evaluated giredestrant as an adjuvant endocrine treatment for patients with early-stage breast cancer. The study met its primary endpoint “showing a improvement statistically significant e clinically significant survival freedom from invasive disease with giredestrant compared with standard endocrine therapy”. The drug was well tolerated.
«Today’s results underline the potential giredestrant as a new endocrine therapy for people with early-stage breast cancer,” Levi Garraway, MD, PhD, Chief Medical Officer and Head of Global Product Development at Roche, was quoted in the release. “The long-awaited success has arrived: giredestrant is effective against early-stage breast cancer,” said Vontobel analysts. development program the drug clinic extends to multiple treatments and therapeutic pathways, which showed further positive results from Roche clinical trials, the experts added.
